Table 2.
Percentage of sustained virological response according to demographics and clinical characteristics
RVR1 | 66.5% |
HCV-RNA negative at EOT | 70.1% |
Relapse2 | 7.3% |
SVR 123 | 62.7% |
Age | |
< 50 yr | 67.4% |
50-65 yr | 63.1% |
> 65 yr | 55.3% |
Previous treatment | |
Naive | 65.7% |
Relapser | 73.7% |
Partial responder | 67.2% |
Null responder | 55.1% |
Fibrosis (%) | |
F1 | 72.7% |
F2 | 73.4% |
F3 | 63.3% |
F4 | 53.4% |
F4 > 65 yr | 43.8% |
HCV-RNA negative at week 4;
Those who achieved EOT but had HCV-RNA positive at week 12;
HCV-RNA negative 12 wk after the EOT. RVR: Rapid virological response; EOT: End of treatment; SVR: Sustained virological response; HCV: Hepatitis C virus.